Flanimus

Company Overview

Snapshot

Founded in May 2020 by Gabby Sarusi, Flanimus operates with 1–10 employees. The company is currently in the Pre-Funding stage and is developing a breathalyzer test for diagnosing coronavirus, which is in clinical trial.

Business overview

Flanimus is a Health Tech & Life Sciences company focused on developing a simple, one-minute breathalyzer test for diagnosing the coronavirus. Its core technology involves a disposable capsule with a chip and a spectrometer that detects the viral spectral signature using proprietary software. This medical device is designed for use at any location by any operator, eliminating the need for trained staff or dedicated labs. Flanimus serves the digital healthcare and medical technologies sectors, with potential applications in markets such as airports.

Company Intelligence Q&A

What is Flanimus's primary product?

Flanimus is developing a one-minute breathalyzer test designed for diagnosing the coronavirus. The test utilizes a disposable capsule and a spectrometer to detect the virus's spectral signature.

What is the current stage of product development for Flanimus?

Flanimus's coronavirus breathalyzer test is currently in the clinical trial stage of development.

Who founded Flanimus?

Flanimus was founded by Gabby Sarusi in May 2020.

What problem does Flanimus aim to solve?

Flanimus aims to provide a rapid, accessible, and cost-effective solution for coronavirus diagnosis, bypassing the need for specialized personnel or laboratory settings.

In which sectors does Flanimus operate?

Flanimus operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Digital Healthcare, with an emphasis on diagnostics.